While CELF2 expression is a marker of good prognosis in low-grade glioma (Supplementary Figure S2), we found conversely that CELF2 had no prognostic value in GBMs (Figure 1E), with the exception of classical non-methylated subtypes on the promoter of MGMT, where high CELF2 expression was of poor prognosis (Figure 1F). The gene discussed is MGMT; the disease is central nervous system cancer.